Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation

Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors

Oncotarget ◽

10.18632/oncotarget.19681 ◽

2017 ◽

Vol 8 (59) ◽

pp. 99429-99437 ◽

Cited By ~ 6

Author(s):

Guangzhi Ma ◽

Jing Zhang ◽

Hai Jiang ◽

Nannan Zhang ◽

Liyuan Yin ◽

...

Keyword(s):

Kinase Inhibitors ◽

Acquired Resistance ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

T790m Mutation ◽

Lung Cancer Patients ◽

Egfr Tyrosine Kinase Inhibitors ◽

Epidermal Growth ◽

Egfr Mutant

Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors

Thoracic Cancer ◽

10.1111/1759-7714.12304 ◽

2015 ◽

Vol 7 (2) ◽

pp. 161-166 ◽

Cited By ~ 8

Author(s):

Sung Hoon Sim ◽

Seung‐Hoon Beom ◽

Yong‐Oon Ahn ◽

Bhumsuk Keam ◽

Tae Min Kim ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Significant Prognostic Factor ◽

Small Cell Lung ◽

Neutrophil Lymphocyte Ratio ◽

Lung Cancer Patients ◽

Epidermal Growth ◽

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

International Journal of Cancer ◽

10.1002/ijc.32025 ◽

2019 ◽

Vol 144 (11) ◽

pp. 2887-2896 ◽

Cited By ~ 6

Author(s):

Yen‐Ting Lin ◽

Jin‐Shing Chen ◽

Wei‐Yu Liao ◽

Chao‐Chi Ho ◽

Chia‐Lin Hsu ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

First Line ◽

T790m Mutation ◽

Lung Cancer Patients ◽

Epidermal Growth ◽

Egfr T790m

Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort

Lung Cancer ◽

10.1016/j.lungcan.2020.11.007 ◽

2021 ◽

Vol 151 ◽

pp. 16-19

Author(s):

Swati Soni ◽

Ashu Rastogi ◽

Kuruswamy T. Prasad ◽

Digambar Behera ◽

Navneet Singh

Keyword(s):

Lung Cancer ◽

Thyroid Dysfunction ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Anaplastic Lymphoma ◽

Epidermal Growth

Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)

Cancer ◽

10.1002/cncr.32744 ◽

2020 ◽

Vol 126 (9) ◽

pp. 2024-2033 ◽

Cited By ~ 7

Author(s):

Hongjing Zang ◽

Guoqing Qian ◽

Dan Zong ◽

Songqing Fan ◽

Taofeek K. Owonikoko ◽

...

Keyword(s):

Lung Cancer ◽

Histone Deacetylase Inhibitor ◽

Acquired Resistance ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Deacetylase Inhibitor ◽

Epidermal Growth ◽

Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations

Lung Cancer ◽

10.1016/j.lungcan.2015.01.004 ◽

2015 ◽

Vol 87 (3) ◽

pp. 311-317 ◽

Cited By ~ 31

Author(s):

Chang Dong Yeo ◽

Ki Hoon Park ◽

Chan Kwon Park ◽

Sang Haak Lee ◽

Seung Joon Kim ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Egfr Tyrosine Kinase Inhibitors ◽

Epidermal Growth

Receptor Tyrosine Kinase Inhibitors

Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors

Experimental and Therapeutic Medicine ◽

10.3892/etm.2017.4356 ◽

2017 ◽

Vol 13 (6) ◽

pp. 3067-3074 ◽

Cited By ~ 1

Author(s):

Yitao Wan ◽

Yuan Yuan ◽

Yueyin Pan ◽

Ying Zhang

Keyword(s):

Lung Cancer ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Growth Factor Receptor ◽

Small Cell ◽

High Dose ◽

Small Cell Lung ◽

Epidermal Growth ◽

The impact of ß-blockers in non–small cell lung cancer patients treated with Epidermal Growth Factor Receptor Kinase Inhibitors, Taiwan NHIRD database study.

10.1183/13993003.congress-2018.pa2855 ◽

2018 ◽

Author(s):

Guin Wei Fan ◽

Chun Yu Lin

Keyword(s):

Lung Cancer ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Receptor Kinase ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Epidermal Growth ◽

The Impact

Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer

Medicine ◽

10.1097/md.0000000000027279 ◽

2021 ◽

Vol 100 (37) ◽

pp. e27279

Author(s):

Xia Wang ◽

Zhiqin Lu ◽

Zhimin Zeng ◽

Jing Cai ◽

Peng Xu ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitors ◽

Stereotactic Body Radiation Therapy ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

P8‐75: First‐ or second‐generation epidermal growth factor receptor tyrosine kinase inhibitors in a large real‐world cohort of non‐small cell lung cancer patients

Respirology ◽

10.1111/resp.14150_587 ◽

2021 ◽

Vol 26 (S3) ◽

pp. 317-317

Keyword(s):

Lung Cancer ◽

Receptor Tyrosine Kinase Inhibitors

Receptor Tyrosine Kinase ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Epidermal Growth ◽